Chian Ri-Cheng, Li Jian-Hua, Lim Jin-Ho, Yoshida Hiroaki
Center for Reproductive Medicine Shanghai 10th People's Hospital of Tongji University Shanghai China.
Reproductive Medical Center, Senior Department of Obstetrics and Gynecology The Seventh Medical Center of PLA General Hospital Beijing China.
Reprod Med Biol. 2023 Jul 11;22(1):e12524. doi: 10.1002/rmb2.12524. eCollection 2023 Jan-Dec.
Thousands of healthy babies are born from in vitro maturation (IVM) procedures, but the rate of efficiency differs with the source of immature oocytes obtained. Recently, there are different IVM protocols proposed for infertility treatment and fertility preservation.
Based on the literature, the clinical application for IVM of immature oocytes was summarized.
Immature oocytes may be retrieved from women after priming with or without the use of follicular stimulation hormone (FSH), human chorionic gonadotrophin (hCG) or a combination of both FSH and hCG. Successful pregnancy rates with IVM technology seem to be correlated with the number of immature oocytes obtained. With the source and culture course of immature oocytes, there are various IVM protocols. IVM of immature oocytes is profoundly affected by the culture conditions, but no breakthrough has been made by improving the IVM medium itself. Thus, the clinical application of IVM technology continues to evolve.
IVM technology is a useful technique for infertile women and fertility preservation. Mild stimulation IVF combined with IVM of immature oocytes is a viable alternative to the conventional stimulation IVF cycle treatment as it may prove to be an optimal first-line treatment approach.
数以千计的健康婴儿通过体外成熟(IVM)程序出生,但效率因获取未成熟卵母细胞的来源不同而有所差异。近来,针对不孕症治疗和生育力保存提出了不同的IVM方案。
基于文献,总结未成熟卵母细胞IVM的临床应用情况。
未成熟卵母细胞可在使用或不使用促卵泡激素(FSH)、人绒毛膜促性腺激素(hCG)或FSH与hCG联合用药进行预处理后从女性体内获取。IVM技术的成功妊娠率似乎与获取的未成熟卵母细胞数量相关。根据未成熟卵母细胞的来源和培养过程,有多种IVM方案。未成熟卵母细胞的IVM受到培养条件的深刻影响,但在改进IVM培养基本身方面尚未取得突破。因此,IVM技术的临床应用仍在不断发展。
IVM技术对于不孕女性和生育力保存是一项有用的技术。轻度刺激体外受精联合未成熟卵母细胞IVM是传统刺激体外受精周期治疗的一种可行替代方案,因为它可能被证明是一种最佳的一线治疗方法。